Skinvisible

Skinvisible owns the Invisicare polymer delivery system, a patented formulation technology that binds to active ingredients and releases them on the skin over an extended period. The polymer is designed to be non-comedogenic and water-resistant, allowing for controlled, sustained release in products ranging from sunscreens to prescription creams. The company holds over 70 patents globally covering the polymer composition, manufacturing steps, and specific product formulations.

Skinvisible operates primarily as a technology licensor rather than a product manufacturer. It earns revenue through upfront license fees, milestone payments tied to regulatory approvals or sales thresholds, and ongoing royalties on commercial product sales by its partners. Because the company does not own manufacturing plants, its cost structure consists almost entirely of patent maintenance, R&D on new formulations, and administrative overhead.

Skinvisible's licensed formulations have reached commercial markets primarily through partners. A notable example was a medical-grade hand sanitizer licensed to a subsidiary of Beijing Huiyuan Pharmaceutical for distribution in China and Asia. The company has also licensed Invisicare-based pain relief and CBD transdermal delivery formulations to partners in North America and Europe, though the scale of commercial uptake has varied across the portfolio.

Skinvisible has historically been quoted on the OTC market under the symbol SKVI. Public financial disclosures from recent years have consistently described a company with minimal revenue and an operating model dependent on capital raised through private placements and convertible debt to fund ongoing operations while waiting for licensing revenue to materialize from partners' clinical and commercial milestones.

Invisicare is a family of polymer complexes that physically bond to active ingredients and hydrate the outer layer of skin without using traditional penetration enhancers that can cause irritation. The platform attempts to solve a common dermatological problem: the tendency of active ingredients in standard creams to wipe off or evaporate quickly after application. By forming a breathable, water-resistant film, Invisicare extends the contact time between the therapeutic ingredient and the skin, which the company argues can improve efficacy across a range of compounds from sunscreens to prescription anti-inflammatory drugs.

In most cases, Skinvisible licenses Invisicare formulations to partner companies that assume responsibility for clinical development and regulatory filings. Skinvisible's typical contribution is the formulation work to combine the partner's active pharmaceutical ingredient with the Invisicare polymer and validate stability. The partner then funds and sponsors the human clinical trials, which is consistent with the company's capital-light licensing model.

In the broader topical drug delivery space, competitors include companies such as Ensign Pharmaceutical, which develops polymer-based delivery systems for dermatology, and larger specialty pharma firms with proprietary dermal platforms. However, Skinvisible's narrow focus on licensing a single platform to multiple partners across OTC and prescription categories sets it apart from competitors that typically pursue their own branded drug pipeline and shoulder clinical trial risk internally.